We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Elsewhere, medical diagnostics provider Angle jumped 28% after it said it has signed a supplier agreement with FTSE 100-listed pharmaceutical firm AstraZeneca.
The AIM listing explained that the contract is to develop and validate a methodology leveraging Angle's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
Chief Executive Andrew Newland commented: "This is Angle's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business. It demonstrates the importance of CTC analysis and is a validation of Angle's Parsortix system. Angle is also working to expand its DDR work with other large pharma customers and continues to generate significant new customer interest through its business development activity."
Https://www.lse.co.uk/ShareBrokerTips.html?shareprice=AGL&share=Angle
Broker Rating 70p
Reducing my holding what had started to get rather too large! However AGL in still my biggest investment..............
To me there are 3 things that are really important here. First and second we know they are talking to both Eisai In. (a top 100 Japanese Company AND now Astrazeneca. Then to me the announcement of 4th January. Why? Because ANY Company doing a drug trial involving a metastasized cancer SIMPLY MUST AS THAT RNS says carry out "Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample". See:-
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
Failure to do an analysis on both the CtDNA and CTC's (Circulating tumour cells) after AGL's RNS explaining the additional important information they found is NOT AN OPTION. It would be a complete dereliction of duty!
When the first contract lands for this service the £1.60 spike on FDA approval might again be reached!!!!
All IMHO.
As a private individual investor in the US I would not count on overseas support. It is down right difficult to purchase shares independently. Schwab and IBKR would not allow direct trading on the AIM exchange. I bought shares OTC where volume is miserable. Maybe institution buyers using a UK broker but it is not easy for individual investors in the US.
FL
NT to buy at 16p and people are selling...as normal...mm's just love it
Mms trying their best to not let 17 go. Once 17 is gone mms will be scrapping for shares
You are right. Hype, being the operative word. Have been hearing this since FDA clearance.
Lets see how high it goes??
Hi Bantham
It’s clear to see we both see the company and its potential in very different lights.
I have an average of 12p and despite the size of my investment, across my entire portfolio I’m not too exposed. So I’m very happy to let it play out.
Since I initially bought in around December ‘23 I’ve personally been impressed with the progress (admittedly I hadn’t seen the company as investable prior and avoided suffering the false starts many on here have mentioned).
Happy to let this one ride for the time being.
L2 auction times during the day
Where can I see the trades taking place?
Hilarious they clear the big auction seller and the pi's see that and start selling I'm shaking my head here...clueless
#historyrhymes?
Auction is interesting 165k of buy orders at 17p so far and the 458k sell order from the open at 16p has returned which I think it will get took out this time and then the breaks are off
I think the penny is dropping and it's about to break the intraday high set first thing at the open which is extremely bullish.
Must admit I did not see it coming but not complaining can it repeat previous spike and break 20p then 25p today ?
Hi TomHuk
I listened to the proactive thing with what i hope was an open mind.
But it seemed to me the same hyping approach is alive and well.
He leads with saying 140,000 patients each with 3 time points with each time point being worth at least £2,000 to Angle.
So you add that up and he’s saying there is potential for £840m revenues just from AZ. I mean - really?
You will remember he threw out similar kinds of numbers when he talked about Eisai. So just from these two there’s potential for £1.6 BILLION of revenues. Incredible.
Then he offers forecasts of perhaps more sensible figures of £2-£5m and £5-£8m i assume in the not too distant future - 12 to 18 months maybe?
I really don’t know how anyone takes this company seriously.
I just think the way he talks makes this uninvestable for anything other than day trading.
Clearly it’s a dead duck on AIM - he needs a lot of money by 1H 2025. I simply can’t see any institution investing behind him and his FINANCIAL track record.
Maybe he will be able to do a Redx and go off market with private investment support. If so, i might join in and would hope to do so at a fraction of today’s price as i was able to do in that situation.
I have made my own mistakes believing in purveyors of miracles - recently a big mistake with Destiny. Whatever happens to the price in the next few days / weeks ( and i do assume it will spike strongly ), my head tells me it’s one to continue avoiding. But good luck with your investment.
Dibs, the contract value may not be large but I think you are missing the point when you call it “derisory”. The importance of the contract is that it is a foot in the door of a major pharmaceutical company.
AS himself, in today’s interview, acknowledged that £150,000 is a small amount of money, but it has a “massive flow through potential”. AGL will aim to build on this new relationship with AstraZeneca. AN also referred to
“the halo effect of working with AstraZeneca” and that “they are a critical reference customer for the rest of our business.” It is a huge endorsement of AGL and Parsortix to be used by a company of the stature of AstraZeneca, who are a genuine household name.
Another positive is that the DDR assay developed and paid for by Artios is being used and developed further for AstraZeneca’s requirements. So, not only have AGL been paid to develop the Artois assay, but it can then be offered to other customers.
I think it’s a great result from the AGL team.
1 mm waiting on 22. Brakes off
Ticking up nicely although I see that every time a chunky buy goes through it is followed by a sell. Looks to me like someone is short here and is trying to depress the sp.
I agree BrnetPeter. LSE is behaving like a 3rd world market. Is it any wonder companies are delisting. However AGL has a US presence in the OTC market I think - ticker ANPCY. I know I will be corrected if I'm wrong about this!!
NG
AGL does well in the afternoon after a cracking RNS
20p finish my prediction, slowly but surely this will re-rate IMHO
Not Investment Advice
Always DYOR
Treeman remember when you used to ramp SCE ON THIS BOARD when it was 70p, where is it now 3p. You used to praise the DCE board.. you don't have a clue do you?
If this was fully listed in the USA the price would be nearly one pound. The company could raise 50 million dollars of new money. The buyers would be piling in today. The Lse is pathetic
Hi Bantham,
Yeah certainly the market is more cautious of spikes after the last rise to 35p. So, hopefully we might see a more gradual organic rise in the coming weeks.
Over the past couple of months I’ve traded in and out about 10-15% of my holding to increase my core position so now holding a decent amount for the long game.
US investors will push this higher.
In the Jan presentation management said main investors our from the US.
Ah Earl you just cannot help yourself can you. I just knew you would be pumping something else for your daily 2-5%.
Better off buying AGL looks like it's going to push on despite me thinking it would go quiet, this is how the super spike of 12-37p started, got to 16-17p looked like it would go dead then in the afternoon it hit a new intraday high and then went nuts. Got to break 17.5p for that here today